Filing Flows › Pacira BioSciences (PCRX) › Q3 2026 › vs Q2 2026
Pacira BioSciences (PCRX) Q3 2026 vs Q2 2026 (quarter over quarter)
Pacira BioSciences's revenue fell $15.7M (-8%) from $192M in Q2 2026 to $177M in Q3 2026. Operating margin 12.6% against 2.2% (+10.4 pts).
Pacira BioSciences, Q3 2026: revenue $177M (-2% year over year), operating margin 12.6%, net earnings $28.5M, operating cash flow $50.1M. The chart draws each line against Q2 2026, the increases inside each band.
Margins
| Q3 2026 | Q2 2026 | Change | |
|---|---|---|---|
| Operating margin | 12.6% | 2.2% | +10.4 pts |
| Net margin | 16.1% | 2.4% | +13.7 pts |
| Free cash flow margin | 26.3% | 29.2% | -2.9 pts |
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $177M | $192M | −$15.7M | -8% |
| Other income, net | $6.5M | −$1.7M | $8.3M | — |
| Operating profit | $22.3M | $4.3M | $18.0M | +422% |
| Costs & expenses | $154M | $188M | −$33.8M | -18% |
| Pre-tax earnings | $28.8M | $2.6M | $26.3M | 11× |
| Cost of revenue | $37.2M | $44.2M | −$6.9M | -16% |
| Research & development | $26.7M | $30.2M | −$3.6M | -12% |
| SG&A | $83.8M | $91.8M | −$8.0M | -9% |
| Other operating costs | $6.6M | $21.9M | −$15.3M | -70% |
| Net earnings | $28.5M | $4.7M | $23.9M | +513% |
| Income tax | $293K | −$2.1M | $2.4M | — |
| Depreciation & amortization | $19.3M | $21.3M | −$2.0M | -10% |
| Share-based compensation | $11.8M | $15.0M | −$3.1M | -21% |
| Working capital & other | $9.5M | −$16.6M | $26.1M | — |
| Operating cash flow | $50.1M | $57.5M | −$7.4M | -13% |
| Free cash flow (OCF − capex) | $46.4M | $56.1M | −$9.7M | -17% |
| Capital expenditures | $3.6M | $1.3M | $2.3M | +171% |
Questions
How much did Pacira BioSciences's revenue grow quarter over quarter in Q3 2026?
Pacira BioSciences's revenue fell $15.7M (-8%) from $192M in Q2 2026 to $177M in Q3 2026. Operating margin 12.6% against 2.2% (+10.4 pts).